Related references
Note: Only part of the references are listed.Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization
Silvia Pesce et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
The Unique Molecular and Cellular Microenvironment of Ovarian Cancer
Thomas Worzfeld et al.
FRONTIERS IN ONCOLOGY (2017)
Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer
David L. Hermanson et al.
STEM CELLS (2016)
Cancer Statistics, 2016
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Generation of Highly Cytotoxic Natural Killer Cells for Treatment of Acute Myelogenous Leukemia Using a Feeder-Free, Particle-Based Approach
Jeremiah L. Oyer et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Comparative study of various subpopulations of cytotoxic cells in blood and ascites from patients with ovarian carcinoma
Sarka Lukesova et al.
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY (2015)
The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer
Katayoun Rezvani et al.
FRONTIERS IN IMMUNOLOGY (2015)
B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape
Silvia Pesce et al.
ONCOIMMUNOLOGY (2015)
A Think Tank of TINK/TANKs: Tumor-Infiltrating/Tumor-Associated Natural Killer Cells in Tumor Progression and Angiogenesis
Antonino Bruno et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Primitive Neuroectodermal Tumor in an Ovarian Cystic Teratoma: Natural Killer and Neuroblastoma Cell Analysis
Giovanna Tabellini et al.
CASE REPORTS IN ONCOLOGY (2014)
NK cell-based immunotherapy for malignant diseases
Min Cheng et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2013)
Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model
Melissa A. Geller et al.
CYTOTHERAPY (2013)
Antigen Presenting Cell-Mediated Expansion of Human Umbilical Cord Blood Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity
Nina Shah et al.
PLOS ONE (2013)
Current status and evolution of preclinical drug development models of epithelial ovarian cancer
Panagiotis A. Konstantinopoulos et al.
FRONTIERS IN ONCOLOGY (2013)
Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research
Nuzhat Ahmed et al.
FRONTIERS IN ONCOLOGY (2013)
Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research
Emma Kipps et al.
NATURE REVIEWS CANCER (2013)
A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment
Hagen Kulbe et al.
CANCER RESEARCH (2012)
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
Cecele J. Denman et al.
PLOS ONE (2012)
Targeting natural killer cells and natural killer T cells in cancer
Eric Vivier et al.
NATURE REVIEWS IMMUNOLOGY (2012)
A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer
Melissa A. Geller et al.
CYTOTHERAPY (2011)
Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer
Rachel N. Grisham et al.
IMMUNOTHERAPY (2011)
CD56brightCD16+ NK Cells: A Functional Intermediate Stage of NK Cell Differentiation
Vivien Beziat et al.
JOURNAL OF IMMUNOLOGY (2011)
Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process
Jan Spanholtz et al.
PLOS ONE (2011)
Expansion, Purification, and Functional Assessment of Human Peripheral Blood NK Cells
Srinivas S. Somanchi et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2011)
MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells
Jennifer A. A. Gubbels et al.
MOLECULAR CANCER (2010)
Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells
Mattias Carlsten et al.
JOURNAL OF IMMUNOLOGY (2009)
Inflammation, inflammatory cells and angiogenesis: decisions and indecisions
Douglas M. Noonan et al.
CANCER AND METASTASIS REVIEWS (2008)
Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125)
Jennifer A. Belisle et al.
IMMUNOLOGY (2007)
Pattern and prognostic factors in patients with malignant ascites: a retrospective study
A. A. Ayantunde et al.
ANNALS OF ONCOLOGY (2007)
The NCI60 human tumour cell line anticancer drug screen
Robert H. Shoemaker
NATURE REVIEWS CANCER (2006)
NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma
HP Dong et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2006)
Intraperitoneal cisplatin and paclitaxel in ovarian cancer
DK Armstrong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Social support, psychological distress, and natural killer cell activity in ovarian cancer
SK Lutgendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: Implications for patient management and clinical trial design
M Markman et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
RF Ozols et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells
J Clausen et al.
IMMUNOBIOLOGY (2003)
Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer
FR Villegas et al.
LUNG CANCER (2002)
Share Paper
